Theodoros Panoskaltsis

Prof. Dr. Theodoros Panoskaltsis

Gynaecological Oncology Unit, 2nd Academic OBGYN Dept, Aretaieion University Hospital, Athens, GR, National and Kapodistrian University of Athens, Athens, Attikí, Greece
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2005 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
WSWilliam Patrick Soutter
William Patrick Soutter
PSPeter Sasieni
Peter Sasieni
TPTheodoros Panoskaltsis
Theodoros Panoskaltsis

5 August 2023 in Life
Verified
Journal Article
Open access
PDF file
Alkis MatsasAlkis Matsas
Alkis Matsas
DSDimitrios Stefanoudakis
Dimitrios Stefanoudakis
TTTheodore Troupis
Theodore Troupis
KKKonstantinos Kontzoglou
Konstantinos Kontzoglou
Makarios EleftheriadesMakarios Eleftheriades
Makarios Eleftheriades
DIDimitrios C. Iliopoulos
Dimitrios C. Iliopoulos
Ovarian cancer (OC) is characterized by silent progression and late-stage diagnosis. It is critical to detect and accurately diagnose the disease early to improve survival rates. Tumor markers have emerged as valuable tools in the diagnosis and management of OC, offering non-invasive and cost-effective options for screening, monitoring, and prognosis. Purpose: This paper explores the diagnostic importance of various tumor markers including CA-125, CA15-3, CA 19-9, HE4,hCG, inhibin, AFP, and LDH, and their impact on disease monitoring and treatment response assessment. Methods: Article searches were performed on PubMed, Scopus, and Google Scholar. Keywords used for the searching process were “Ovarian cancer”, “Cancer biomarkers”, “Early detection”, “Cancer diagnosis”, “CA-125”,“CA 15-3”,“CA 19-9”, “HE4”,“hCG”, “inhibin”, “AFP”, “LDH”, and others. Results: HE4, when combined with CA-125, shows improved sensitivity and specificity, particularly in early-stage detection. Additionally, hCG holds promise as a prognostic marker, aiding treatment response prediction and outcome assessment. Novel markers like microRNAs, DNA methylation patterns, and circulating tumor cells offer potential for enhanced diagnostic accuracy and personalized management. Integrating these markers into a comprehensive panel may improve sensitivity and specificity in ovarian cancer diagnosis. However, careful interpretation of tumor marker results is necessary, considering factors such as age, menopausal status, and comorbidities. Further research is needed to validate and refine diagnostic algorithms, optimizing the clinical significance of tumor markers in ovarian cancer management. In conclusion, tumor markers such as CA-125, CA15-3, CA 19-9, HE4, and hCG provide valuable insights into ovarian cancer diagnosis, monitoring, and prognosis, with the potential to enhance early detection.

25 March 2011 in Histopathology
Verified
Journal Article
Closed access
PDF file
KPKitty Pavlakis
Kitty Pavlakis
IMIrini Messini
Irini Messini
TVThomas Vrekoussis
Thomas Vrekoussis
TPTheodoros Panoskaltsis
Theodoros Panoskaltsis
DCDimitris Chrysanthakis
Dimitris Chrysanthakis
ZVZannis Voulgaris
Zannis Voulgaris

1 March 2000 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
TPTheodoros Panoskaltsis
Theodoros Panoskaltsis
DMDavid A. Moore
David A. Moore
DHDimitrios A. Haidopoulos
Dimitrios A. Haidopoulos
AMAngus G. McIndoe
Angus G. McIndoe

1 January 2017 in Medicine
Verified
Journal Article
Open access
DVDennis Vaidakis
Dennis Vaidakis
IMIrini Moustaki
Irini Moustaki
IZIoannis Zervas
Ioannis Zervas
ABAnastasia Barbouni
Anastasia Barbouni
KMKyriaki Merakou
Kyriaki Merakou
TPTheodoros Panoskaltsis
Theodoros Panoskaltsis
The aim of the present study was to identify the sexual behavior, attitudes, beliefs, and knowledge on sexually transmitted infections (STIs) focused on human papilloma virus (HPV) in the Greek adolescent population. The participants were 4547 adolescents, a representative sample for Greek territory with a mean age of 17 years. After written permission from Greek ministry of education each student completed a questionnaire with 36 questions. The fields covered were demographic characteristics, sexual life data, and basic knowledge on HPV. In the present study, 43% and 75% of the participants knew about HPV or cervical cancer, while more than 6 out of 10 did not know the association between the 2. More than 60% of the participants could not answer correctly neither about HPV infection and cervical cancer frequency in sexually active women, nor about protection methods against HPV and cervical cancer. This study shows that the low vaccination coverage of the Greek population may be due to lack of information and awareness of the adolescents and their parents. It is our duty to increase our efforts in order to better educate the population and vaccinate the population as early as possible in their reproductive years.

1 October 2019 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
TATheodoros Agorastos
Theodoros Agorastos
KCKimon Chatzistamatiou
Kimon Chatzistamatiou
ATAthena Tsertanidou
Athena Tsertanidou
EMEvangelia Mouchtaropoulou
Evangelia Mouchtaropoulou
KPKonstantinos Pasentsis
Konstantinos Pasentsis
KSKostas Stamatopoulos
Kostas Stamatopoulos
Self-sampling for human papillomavirus (HPV) testing is an alternative to physician sampling particularly for cervical cancer screening nonattenders. The GRECOSELF study is a nationwide observational cross-sectional study aiming to suggest a way to implement HPV-DNA testing in conjunction with self-sampling for cervical cancer screening in Greece, utilizing a midwifery network. Women residing in remote areas of Greece were approached by midwives, of a nationwide network, and were provided with a self-collection kit (dry swab) for cervicovaginal sampling and asked to answer a questionnaire about their cervical cancer screening history. Each sample was tested for high-risk (hr) HPV with the Cobas HPV test. HrHPV-Positive women were referred to undergo colposcopy and, if needed, treatment according to colposcopy/biopsy results. Between May 2016 and November 2018, 13,111 women were recruited. Of these, 12,787 women gave valid answers in the study questionnaire and had valid HPV-DNA results; hrHPV prevalence was 8.3%; high-grade cervical/vaginal disease or cancer prevalence was 0.6%. HrHPV positivity rate decreased with age from 20.7% for women aged 25–29 years to 5.1% for women aged 50–60 years. Positive predictive value for hrHPV testing and for HPV16/18 genotyping ranged from 5.0% to 11.6% and from 11.8% to 27.0%, respectively, in different age groups. Compliance to colposcopy referral rate ranged from 68.6% (for women 25–29) to 76.3% (for women 40–49). For women residing in remote areas of Greece, the detection of hrHPV DNA with the Cobas HPV test, on self-collected cervicovaginal samples using dry cotton swabs, which are provided by visiting midwives, is a promising method for cervical cancer secondary prevention.